Lipocine Inc.
LPCN
$3.03
$0.01410.47%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -12.35% | -22.00% | 492.81% | 358.33% | 8,629.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -12.35% | -22.00% | 492.81% | 358.33% | 8,629.09% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -12.35% | -22.00% | 492.81% | 358.33% | 8,629.09% |
| SG&A Expenses | -25.27% | -12.42% | 1.97% | 12.92% | 19.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.53% | -32.75% | -18.08% | -10.89% | 5.06% |
| Operating Income | 42.52% | 37.63% | 93.56% | 70.42% | 29.43% |
| Income Before Tax | 46.90% | 40.12% | 100.06% | 75.12% | 29.61% |
| Income Tax Expenses | -84.62% | -12.50% | -12.50% | 85.71% | 85.71% |
| Earnings from Continuing Operations | 46.90% | 40.12% | 100.05% | 75.12% | 29.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 46.90% | 40.12% | 100.05% | 75.12% | 29.60% |
| EBIT | 42.52% | 37.63% | 93.56% | 70.42% | 29.43% |
| EBITDA | 42.90% | 37.90% | 93.78% | 70.57% | 29.57% |
| EPS Basic | 47.32% | 41.01% | 100.16% | 75.57% | 30.57% |
| Normalized Basic EPS | 47.32% | 41.02% | 100.17% | 75.58% | 30.58% |
| EPS Diluted | 44.93% | 39.01% | 98.70% | 75.02% | 32.51% |
| Normalized Diluted EPS | 46.26% | 40.05% | 99.37% | 75.41% | 30.32% |
| Average Basic Shares Outstanding | 0.60% | 1.08% | 1.32% | 1.56% | 1.57% |
| Average Diluted Shares Outstanding | 1.98% | 2.46% | 3.10% | 1.76% | 1.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |